首页> 外文期刊>Journal of International Medical Research >Weighted gene expression profiles identify diagnostic and prognostic genes for lung adenocarcinoma and squamous cell carcinoma
【24h】

Weighted gene expression profiles identify diagnostic and prognostic genes for lung adenocarcinoma and squamous cell carcinoma

机译:加权基因表达谱鉴定肺腺癌和鳞状细胞癌的诊断和预后基因

获取原文
           

摘要

Objective To construct a diagnostic signature to distinguish lung adenocarcinoma from lung squamous cell carcinoma and a prognostic signature to predict the risk of death for patients with nonsmall-cell lung cancer, with satisfactory predictive performances, good stabilities, small sizes and meaningful biological implications. Methods Pathway-based feature selection methods utilize pathway information as a priori to provide insightful clues on potential biomarkers from the biological perspective, and such incorporation may be realized by adding weights to test statistics or gene expression values. In this study, weighted gene expression profiles were generated using the GeneRank method and then the LASSO method was used to identify discriminative and prognostic genes. Results The five-gene diagnostic signature including keratin 5 ( KRT5 ), mucin 1 ( MUC1 ), triggering receptor expressed on myeloid cells 1 ( TREM1 ), complement C3 ( C3 ) and transmembrane serine protease 2 ( TMPRSS2 ) achieved a predictive error of 12.8% and a Generalized Brier Score of 0.108, while the five-gene prognostic signature including alcohol dehydrogenase 1C (class I), gamma polypeptide ( ADH1C ), alpha-2-glycoprotein 1, zinc-binding ( AZGP1 ), clusterin ( CLU ), cyclin dependent kinase 1 ( CDK1 ) and paternally expressed 10 ( PEG10 ) obtained a log-rank P -value of 0.03 and a C-index of 0.622 on the test set. Conclusions Besides good predictive capacity, model parsimony and stability, the identified diagnostic and prognostic genes were highly relevant to lung cancer. A large-sized prospective study to explore the utilization of these genes in a clinical setting is warranted.
机译:目的构建诊断签名,以区分肺鳞状细胞癌的肺腺癌和预后签名,以预测非体细胞肺癌患者死亡风险,具有令人满意的预测性能,良好的稳定性,小尺寸和有意义的生物意义。方法基于途径的特征选择方法利用途径信息作为优先考虑来自生物学视角的潜在生物标志物上的洞察线索,并且可以通过添加重量来测试统计或基因表达值来实现这种掺入。在该研究中,使用通常的方法产生加权基因表达谱,然后使用套索方法来鉴定鉴别性和预后基因。结果包括角蛋白5(KRT5),粘蛋白1(MUC1),在骨髓细胞1(TREM1),补体C3(C3)和跨膜丝氨酸蛋白酶2(TMPRSS2)中表达的触发受体,达到预测误差12.8的预测误差%和广义Brier得分为0.108,而五基因预后签名包括醇脱氢酶1C(I类),γ-2-糖蛋白1,锌结合(AZGP1),聚氨酯(CLU),细胞周期蛋白依赖性激酶1(CDK1)和患者表达10(PEG10)获得了在试验组上的0.03和0.622的0.03和C折射率的对数。结论除了良好的预测能力,模型分析和稳定性,鉴定的诊断和预后基因与肺癌高度相关。探讨临床环境中利用这些基因的大型前瞻性研究是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号